100 million market cap could be fairly priced anyway. That is still pretty significant based on where the drugs currently are. The stock could move up significantly with Promising results from B-UP, B-OM, P, and Kevetrin.
Biotech doesn't generally trickle up. They spike up. There is something in the results that the big money hasn't seen yet. If there was, the stock wouldn't have dropped so much with the bogus hit pieces. Hopefully they show up in these phase 2's
News 
Market Data 
Discover 
